Resonant plans to raise $9.2 million in public offering
Resonant, a late stage Goleta development company designing small smartphone technology, plans to raise $9.2 million in a public offering. Documents filed with the Securities and Exchange Commission Sept. 9 said the company plans to offer about 2.4 million shares for $4.25 per share. The company expects to complete the offering by Sept. 14. Resonant Read More →
Mission Wealth Management launches Social Values Portfolio
Santa Barbara-based financial advising firm Mission Wealth Management launched its new Social Values Portfolio, which aligns investments with an investor’s values. “The introduction of the Social Values Portfolio is in perfect alignment with Mission Wealth’s purpose as a business to serve both our clients and the community at large,” Mission Wealth CEO and founder Seth Streeter Read More →
Greed drives skyrocketing cost of drugs in the U.S.
This article is only available to Business Times subscribers Subscribers: LOG IN or REGISTER for complete digital access. Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists. Check the STATUS of your Subscription Account.
Fiscal reform needed as pension time bomb ticks away
America’s summer of fiscal discontent is coming to a close on a downbeat note. The California legislature is preparing to wind up its session having stirred up a lot of controversy but done almost nothing to address the state’s ongoing pension crisis. The burgeoning shortfall now adds up to $139 billion in the CalPERS fund Read More →
FDA approves Amgen’s Blincyto
The U.S. Food and Drug Administration approved Amgen’s drug Blincyto for treating pediatric leukemia patients Sept. 1. In Dec. 2014, the FDA approved Blincyto to treat patients with precursor B-cell acute lymphoblastic leukemia, which is a rare form of the disease. On Sept. 1, the agency extended Blincyto’s approval to include pediatric patients with another Read More →
Amgen acquires German drug
Story updated at 11 a.m.: Thousand Oaks-based biotech giant Amgen acquired global development rights to a multiple myeloma drug from a German company Sept. 1. Amgen said in a news release it acquired commercial and development rights to BI 836909, which is currently being developed by German company Boehringer Ingelheim. It will work with Boehringer Read More →
Semtech Q2 revenues soar
Semtech revenues increased along with profits and earnings per share during the second quarter of fiscal year 2017 the company announced Aug. 31. Semtech, a Camarillo-based manufacturer of semi-conductors for the smartphone industry, released quarterly earnings results Aug. 31. Revenues increased 8 percent from $125.7 million during the same quarter last year to $135.9 million Read More →
